The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued recommendations that include a Sanofi drug for type‑1 diabetes, Eli Lilly’s oral selective estrogen receptor degrader (SERD) for a subset of breast cancers, and five additional products under review. The slate included a gene‑therapy recommendation originating from Fondazione Telethon for Wiskott‑Aldrich syndrome. The CHMP endorsements mark important regulatory momentum in endocrinology, oncology and rare‑disease gene therapy, and will now move to member‑state decision processes. For biotech companies, CHMP support often precedes market entry in major EU markets and signals commercial viability to partners and investors. These recommendations underscore regulators’ continued receptivity to innovative modalities — small molecules, oral degraders and ex‑vivo gene therapies — while highlighting the varied evidentiary expectations across therapeutic areas.